GP Pharm is a privately owned pharmaceutical company, founded in 2000 and located in L’Hospitalet de Llobregat (Barcelona, Spain). GP Pharm specializes in the development, manufacturing, and marketing of complex and/or generic peptide-based injectable products. Our products are based on proprietary drug delivery systems, developed in-house, utilizing technological platforms such as microspheres, liposomes, and/or peptide APIs. The company’s core therapeutic areas include Urology, Oncology, and Women’s Health. GP Pharm’s business activities are focused on: Out-licensing of our proprietary portfolio, In-licensing for the Spanish market, and CDMO (Contract Development and Manufacturing Organization) services. To expand our international presence, GP Pharm seeks to collaborate with well-established pharmaceutical companies to promote and distribute its portfolio through licensing agreements. Additionally, GP Pharm offers CDMO services to third-party pharmaceutical companies. We are equipped to manufacture injectable oncology products, high-potency injectable products (including oligonucleotides, peptides, etc.), and advanced drug delivery systems (liposomes and microspheres), all under GMP authorization. GP Pharm has been successfully audited by various health authorities, including those from Europe, the USA, Japan, Australia, Canada (mutual recognition), among others. For further information, please visit our website: www.gp-pharm.com
Gador S.A.
Gador is a leading Argentine pharmaceutical company. For the last 82 years, its mission has been to investigate, develop, manufacture and commercialize the best quality medicines for every patient at affordable prices. Gador continuously invests in product technology and quality control, according to international standards and maintains a large updated portfolio of pharmaceutical products. Our company is currently focused on biopharmaceutics as a source of innovation and generation of new therapeutic resources for its territory, which is expanded throughout Latin America. Gador has a longstanding experience in the commercialization of special products, either own products or licenses from world renowned companies, such as Gilead Sciences Ltd, Astellas Pharma, Eli Lilly, Coherus, Viatris, MSD, Novartis, Cipla, among others. As a leader company in the market, Gador has undertaken an ambitious program in this area, which involves: Licenses of new products approved or at their last clinical development stage Commercialization of a new-generation biosimilar Development and commercialization of new biopharmaceuticals with focus in special products and rare disease | Gador is a leading Argentine pharmaceutical company. For the last 82 years, its mission has been to investigate, develop, manufacture and commercialize the best quality medicines for every patient at affordable prices. Gador continuously invests in product technology and quality control, according to international standards and maintains a large updated portfolio of pharmaceutical products. Our company is currently focused on biopharmaceutics as a source of innovation and generation of new therapeutic resources for its territory, which is expanded throughout Latin America. Gador has a longstanding experience in the commercialization of special products, either own products or licenses from world renowned companies, such as Gilead Sciences Ltd, Astellas Pharma, Eli Lilly, Coherus, Sifi, Recordati, Boehringer, Viatris, MSD, Novartis, among others. As a leader company in the market, Gador has undertaken an ambitious program in this area, which involves: Licenses of new products approved or at their last clinical development stage Commercialization of a new-generation biosimilar Development and commercialization of new biopharmaceuticals with focus in special products and rare disease | Gador is a leading pharmaceutical Company that investigate, develop, manufacture and commercialize medicinal products for human use. It is based in Argentina since 1940 and today covers the whole Latin America through own affiliates or a net of exclusive distributors. Gador continuously invests in product technology, quality control and new facilities development, according to international standards and approvals such as FDA, EMA, KFDA, COFEPRIS, TGA, among others.. Our company is currently focused on innovative therapies and products, such as biopharmaceutics, oligonucleotides and gene therapies as a source of generation of new therapeutic resources for its territory, which is expanded throughout Latin America. Gador has a long-standing experience in the commercialization of special and primary care products, either own products or licenses from world renowned companies, such as Gilead Sciences, Astellas, MSD, Boehringer Ingelheim, Recordati, Viatris, Sifi, Galderma, Besins, among others. As a leader company in the market, Gador has undertaken an ambitious program in this area, which involves: Licenses of new products approved or at their last clinical development stage Commercialization of a new-generation biosimilar Development and commercialization of new biopharmaceuticals with focus in special products and rare disease In addition, Gador´s main shareholders have created a new development company: Qualix Dot (Design on Therapies). Qualix DoT is the research and development pharmaceutical company of Qualix Ventures.The purpose of Qualix DoT is to explore, drive, and collaborate in world-class innovative projects that come from academic or industrial initiatives by mainly repurposing known compounds for new indications. Qualix DoT adopts a collaborative business model whereby it works in partnership with academic, industrial and patients’ organizations. Biopharmaceuticals – rare disease – oncology – biosimilars – CAR T – Oligonucleotides y Repurposing
Federal Equipment Company
Federal Equipment Company is a reliable resource for pharmaceutical and biopharmaceutical processing and packaging equipment needs, with over 65 years of expertise working with manufacturers seeking to buy and sell used equipment. For companies with surplus equipment, Federal Equipment Company takes away all the headaches of asset management. We bring deep knowledge of equipment values, supporting accurate appraisals, and advise you on a range of options to optimize the value you recoup. We also offer cash liquidity and fast, expert removal of individual pieces to entire lines – protecting your facility. This activity with reputable companies gives us a continual on-hand inventory of reliable equipment manufactured by leading OEMs. Our market knowledge ensures you buy exactly what you need with fast turnaround. We also offer expert training & troubleshooting for solid dose equipment. | Federal Equipment Company is a trusted source for premium used biotechnology equipment. Recognizing the advanced technologies and precision essential in biotech and biopharmaceutical production, we have methodically curated our inventory to align with the high standards and demands of this pioneering industry sector. Connect with our expert team at BIO International 2025 for a detailed quote on our available biotechnology equipment! | Since 1957, Federal Equipment Company has been a trusted supplier of high-quality used processing and packaging equipment for the plastics and rubber industries. We help manufacturers quickly and reliably source cost-effective machinery for extrusion, compounding, film and sheet, recycling, and downstream converting. Our extensive inventory includes ready-to-ship extruders (single- and twin-screw), pelletizers, blown and cast film systems, granulators, mixers, screeners, and more. We stock equipment from leading OEMs like Davis-Standard, Erema, Cumberland, and Farrel, with detailed listings and photos available at fedequip.com. Buyers choose us for our transparency, speed, and deep industry knowledge. In addition to equipment sales, we offer asset recovery services that help plastics manufacturers maximize value from surplus equipment through resale, redeployment, or auction. Whether you’re scaling production or clearing idle assets, our team delivers dependable solutions and responsive service. Visit us at the AMI Plastics World Expos 2025 or browse our inventory online at fedequip.com.
FAREVA
Farera as a CDMO is providing a large service offer as sterile injectable and high potent, biological drug, conventionnal product, medial devices, foods supllements and probiotics as well as Drug substance manufacturing of recombinant protein, Andibody Dug Conjugason (ADC) with the associated Fill& Finish | FAREVA is a leading global pharmaceutical CDMO with industry leading capabilities in the development and manufacturing of a large range of Drug Products and Active Pharmaceutical Ingredients (APIs). FAREVA employs 13,000 people distributed in 41 production sites located in 13 countries in EMEA and the Americas. 16 of the FAREVA sites are dedicated to pharmaceutical activities. FAREVA’s API division has operations in 3 European sites located in France and Germany. | Fareva is a leading global pharmaceutical CDMO with a network of 16 manufacturing sites and 3 development sites throughout EMEA and the Americans. We offer comprehensive drug product and API services, including formulation development, clinical manufacturing, scale-up, and commercial manufacturing of small and large molecules. Our capabilities cover a wide range of dosage forms, such as OTC products, oral solid doses, non-sterile liquids and solids, ophthalmics, as well as sterile fill/finish and lyophilized presentations. In addition, our facilities have extensive expertise in secondary packaging, enabling us to serve as a fully integrated partner for our clients’ end-to-end pharmaceutical needs.
Cipla
With a 90-year global legacy rooted in care, Cipla has been instrumental in expanding patient access to affordable, high-quality medicines. For over three decades, we’ve delivered innovative generic products and advanced delivery systems to the U.S. pharmaceutical industry. As a first-to-market supplier of 505(b)(2) oncology products, our efforts reflect our enduring commitment to our mission of ‘Caring for Life’. | A global pharmaceutical company whose top priority is ensuring no patient shall be denied access to high quality affordable medication and support. Cipla Limited is a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients. For more than 80 years, Cipla has emerged as one of the most respected pharmaceutical manufactures, with a portfolio consisting of 1500+ products, 50+ dosage forms across a wide range of therapeutic categories.
Chitozan Health LLC
Chitozan Health is an antimicrobial company seeking to commercialize antimicrobial materials that minimize the tendency for resistance to develop in bacteria and fungal threats. We are currently focused on launch of an advanced burn and wound gel in collaboration with the Medical University of South Carolina and the Chief of Burn Surgery Dr. Steven Kahn. Other products in stages of development are an antimicrobial flame-resistant textile finish, an anti-fungal barrier packaging coating, topical skin disease treatments, and an inhaled therapeutic for treatment of chronic lung infections caused by pseudomonas aeruginosa and mycobacteria.
BIOPROFARMA BAGO
For more than 15 years Bioprofarma Bagó has been positioned as a laboratory specialized in high-complex treatments with different therapeutical areas and with a wide-range portfolio of health care products. To be part of Bagó Group, with its development, strength and prestige, endorses our new identity. Our history begins in 2003, when Bagó Group became interested in cancer and biotechnology areas. Since that moment, and aiming to offer therapeutic solutions with proven efficacy and quality, our company has been expanding and improving its portfolio with new molecules in order to enlarge the physicians´ treatment decisions for their patients. Currently we have 56 products and 88 approved presentations, which are registered in Argentina, and many of them are also approved by the regulatory agencies in Latin America, Southeast Asia and French speaking Africa. Our portfolio is mainly focused on Hematology, Oncology, Urology, Neurology and Rare Diseases. Besides the products developed in our own laboratory, we have received licenses of multinational companies which have entrusted us the promotion and distribution of their products in Argentina. Focused on being a leader company in medicines for special pathologies in the region, we have recently finished the construction of a new pharmaceutical plant in Argentina. This plant will have two specialized production lines: one for injectable medications (both liquid and lyophilized), and the other one for the development of solid oral products. This new plant will be among the most modern of the country, in compliance not only with the ANMAT standards, but also with the most demanding regulatory authorities in the region. Our purpose is to expand our current exports far beyond our 17 destinations and to reach new territories. We are completely aware that behind each medicine that Bioprofarma Bagó supplies to the market, there is a hope of recovery and an improvement for the quality of a person´s life. This awareness, that demands and commits us to the whole society, is the inspiration and the motivation for meeting better therapeutical alternatives. The importance we give to ensure quality, in compliance with good manufacturing practices, was and will be our basis as a company. Bioprofarma Bagó grows, evolves and is transformed to go beyond the limits of science through safe, efficient and innovative solutions. The constant evolution identifies us and makes us unique.
Arochi & Lindner
Arochi & Lindner: Premier Legal Solutions for the Life Sciences and Pharmaceutical Industries With more than 30 years of experience, Arochi & Lindner is a leading law firm in Mexico and Spain, known for its excellence in Intellectual Property, Litigation, and Regulatory Advisory. Our Life Sciences practice stands out as one of the most robust in the market, providing strategic legal solutions for companies in the pharmaceutical, biotechnology, medical device, food, cosmetics, and agricultural sectors. We recognize that the Life Sciences sector is constantly evolving and encounters complex regulatory challenges. That’s why we offer thorough legal counsel that covers a wide range of services, including trademark and patent registration, obtaining sanitary authorizations from COFEPRIS, drafting licensing agreements, ensuring regulatory compliance, handling patent litigation, and navigating public procurement processes. Our multidisciplinary team — which includes attorneys, chemists, engineers, and biotechnologists — combines technical and legal expertise to provide practical and efficient solutions aligned with our clients’ business goals. We have successfully represented drug companies in high-profile patent disputes and have managed groundbreaking innovations, such as the first microorganism deposit at Mexico’s National Center for Genetic Resources (CNRG). At Arochi & Lindner, we don’t just protect innovation — we empower it. Our mission is to act as a strategic partner for companies transforming health, technology, and quality of life through science.
Apotex Latin America HQ
Apotex is a Canadian based global health company, A Force for Health with a mission to improve everyday access to affordable, innovative medicines and health products for patients and consumers worldwide. Apotex aims to continue developing its positioning as the ideal partner of choice in the Americas – with a very strong presence in North America (Canada, USA, Mexico), and an ongoing geographic expansion towards Central America and South America. As a Canadian company, we strive for excellence and patient impact, and are willing to partner with leading pharmaceutical companies to drive patient access across the entire Latin American region. From our headquarters in Mexico City, our team is capable to develop unique value propositions, which leverages our industrial footprint locally, with one of the largets API manufacturing facilities in the continent, as well as a large finished-good production facility, on top of medical promotion focused on a variety of therapeutic areas for branded and branded generics products, and a fast-growing OTC / consumer health operation. https://apotex.com/global
AmbioPharm, Inc.
AmbioPharm is a global leader in peptide manufacturing, specializing in the development and production of peptide-based Active Pharmaceutical Ingredients (APIs). Founded in 2005 and headquartered in North Augusta, South Carolina, USA, we are a patient-focused Contract Development and Manufacturing Organization (CDMO) with a reputation for technical excellence, innovation, and cost-effective solutions. Our state-of-the-art facilities in South Carolina, USA, and Shanghai, China, manufacture New Chemical Entities (NCEs) and peptide APIs under cGMP compliance, supporting pharmaceutical and biotech clients worldwide. AmbioPharm provides comprehensive peptide manufacturing solutions that support our clients from early-stage development through full-scale commercial production. Our expertise covers solid-phase, solution-phase, and hybrid synthesis, as well as organic conjugations to proteins, toxoids, antifungals, KLH (Keyhole Limpet Hemocyanin), and PEG (Polyethylene Glycol). We offer end-to-end peptide development services, including scale-up, validation, and process qualification leading up to New Drug Application (NDA) submissions with the U.S. Food and Drug Administration (FDA). With our advanced manufacturing facilities, robust quality systems, and cost-effective approach, AmbioPharm is the trusted partner for pharmaceutical and biotech companies seeking high-quality peptide APIs for both clinical and commercial applications. | AmbioPharm is a global peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients.